Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Tyrosine hydroxylase inhibitor for treating intestinal hyperpermeability

A tyrosine hydroxylase inhibitor, a technology of tyrosine hydroxylase, which is applied in the directions of non-central analgesics, anhydride/acid/halide active ingredients, and non-active ingredients medical preparations, etc. Proven safe and effective

Inactive Publication Date: 2016-08-10
史蒂文霍夫曼
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Several drug targets that could potentially promote barrier restoration have been proposed, but none have been proven safe and effective

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Initially 200 patients were screened. Thirty subjects who met the study criteria consented. Nine (9) subjects had high blood sugar levels (hyperglycemia) prior to consent to the study.

[0043]High blood glucose levels (hyperglycemia) were defined as fasting plasma glucose levels of 126 mg / dl or greater on two separate occasions. The mean patient age was 62 years, and the median patient age was 60 years. Six patients were female and three patients were male. Five patients were 50-60 years old, and 4 patients were over 60 years old.

[0044] Patients in the study were administered drugs including tyrosine hydroxylase inhibitors (i.e., α-methyl-DL tyrosine), melanin boosters (i.e., melanotan II), p450 3A4 boosters (i.e., 5 , 5-diphenylhydantoin) and leucine aminopeptidase inhibitors (ie, N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl]-L- leucine) treatment options. The compounds were administered each of 5 days per week for a period of 6 weeks with 1 or 2 days of rest...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (IBD), graft versus host disease (GVHD), HIV / AIDS, multiple organ dysfunction syndrome, irritable bowel syndrome (IBS), celiac disease, eczema, psoriasis, acute pancreatitis, Parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Patent Application No. 14 / 062,165, filed October 24, 2013, which claims the benefit of U.S. Patent Application No. 61 / 894,261, filed October 22, 2013, the entire contents of both are hereby incorporated by reference Incorporated into this article. technical field [0003] The present invention generally relates to compositions, kits and methods for treating intestinal hyperpermeability. Background technique [0004] The intestinal epithelium separates the luminal contents from the interstitium. This function is largely dependent on the integrity of the epithelium and the tight junctions that seal the paracellular space. These intestinal tight junctions are selectively permeable. This permeability may increase physiologically in response to the presence of luminal nutrients. Permeability can also be pathologically increased by mucosal immune cells and cytokines, the enter...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/223A61K31/325A61K31/198A61K31/4166A61K31/55A61K45/06A61P1/00A61P3/10A61P21/00A61P37/06A61P31/18A61P1/12A61P17/00A61P17/06A61P1/18A61P29/00A61P25/16A61P25/24A61P11/06A61P37/00A61P19/02A61P1/16A61P3/02A61P25/00A61K31/19
CPCA61K31/19A61K31/198A61K31/223A61K31/325A61K31/4166A61K31/55A61K45/06A61K2300/00A61K31/436A61K31/20A61K31/216A61K31/37A61K9/0014A61K47/10A61K47/12A61K47/22A61P1/00A61P1/04A61P1/12A61P1/16A61P1/18A61P11/00A61P11/06A61P17/00A61P17/06A61P19/00A61P19/02A61P21/00A61P25/00A61P25/16A61P25/24A61P29/00A61P3/00A61P3/02A61P31/18A61P3/06A61P37/00A61P37/06A61P37/08A61P43/00A61P3/10A61K38/34
Inventor 史蒂文·霍夫曼
Owner 史蒂文霍夫曼
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com